Maeva C.
- Country
- France
- Department
- Hepatogastroenterology
Research Overview
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- A Study to Test How Well Obefazimod Works and How Safe It Is for Patients with Moderately to Severely Active Ulcerative Colitis
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of Tulisokibart Efficacy and Safety in Moderately to Severely Active Crohn's Disease
Data & Insights
Has run more than one trial at 202 of 308 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in treating inflammatory bowel diseases, with particular emphasis on developing therapeutic approaches for moderate to severe cases.
- Ulcerative Colitis Management
- Crohn's Disease Treatment
- Novel Therapeutic Evaluation
Focuses on investigating innovative treatment options for patients with inadequate response to conventional therapies.
Therapeutic Development
Contributes to advancing treatment methodologies for gastrointestinal conditions, particularly focusing on comparative efficacy studies.
- Clinical Remission Studies
- Endoscopic Improvement Assessment
- Long-term Treatment Evaluation
Specializes in evaluating therapeutic interventions for achieving symptomatic remission in chronic inflammatory conditions.
Clinical Expertise
Demonstrates significant experience in gastroenterological research, particularly in treating resistant forms of inflammatory bowel conditions.
- Treatment-Resistant Cases
- Maintenance Therapy Studies
- Safety and Efficacy Assessment
Dedicated to investigating therapeutic options for patients who have not responded to traditional treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.